Literature DB >> 7039036

Effect of cyclosporin A on allotransplanted pancreatic fragments to the spleen of totally pancreatectomized dogs.

D F Du Toit, H Reece-Smith, P McShane, T Denton, P J Morris.   

Abstract

Cyclosporin A (Cy A) was evaluated in dogs to assess its effectiveness of prolonging survival of allogeneic pancreatic islet tissue transplanted to the spleens of totally pancreatectomized mongrel dogs. Thirty-seven dogs were made diabetic by total pancreatectomy. Ten untreated pancreatectomized animals survived a mean (+/-SE) of 6.3 +/- 0.9 days and died with mean (+/-SE) plasma glucose levels of 23.2 +/- 2.7 mmol/liter. Dispersed pancreatic fragments, prepared by collagenase digestion without separation of exocrine and endocrine components, were directly implanted into the splenic pulp of 27 pancreatectomized dogs. Twelve dogs given autotransplants became normoglycemic after 4.3 +/- 0.5 days and remained so until killed at 60 days post-transplant, although normal glucose tolerance tests were not achieved. Eight nonimmunosuppressed dogs given allogeneic pancreatic fragments did not become normoglycemic but survived for 13.0 +/- 2.1 days, the dogs dying with a terminal plasma glucose of 22.7 mmol/liter. An additional seven dogs given allogeneic transplants were given Cy A (oral solution), 25 mg/kg/day, for 14 days, and, although failing to become normoglycemic, survived for 28.1 +/- 5.4 days and died with terminal plasma glucose levels of 25.1 +/- 0.6 mmol/liter. Intrasplenic complications included subcapsular hematomas, intrasplenic necrosis and cavitation, capsular perforations, and arteriolar thrombosis. The failure to achieve normoglycemia with allogeneic dispersed pancreatic tissue in dogs treated with Cy A and the complications associated with the implantation of the tissue in the spleen do not suggest that this approach is worthy of clinical trial.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7039036     DOI: 10.1097/00007890-198203000-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

Review 1.  Prospects for pancreatic islet transplantation.

Authors:  D W Gray; P J Morris
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

2.  The effects of transplant mass on insulin release by collagenase-dispersed pancreatic fragments in the diabetic dog.

Authors:  D Alderson; J R Farndon
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

3.  Islet autotransplantation in the pancreatectomized dog: effect of time on graft function.

Authors:  D Alderson; J R Farndon; K G Alberti; I D Johnston
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

4.  Cyclosporine and pancreas transplantation.

Authors:  D W Gray; P J Morris
Journal:  World J Surg       Date:  1984-04       Impact factor: 3.352

5.  Experimental vascularized segmental pancreatic and islet transplantation in the baboon.

Authors:  D F du Toit; J J Heydenrych; B Smit; G Louw; T Zuurmond; L Laker; D Els; A Weideman; S Wolfe-Coote; E A van der Merwe
Journal:  World J Surg       Date:  1984-04       Impact factor: 3.352

6.  Prolongation of graft survival in allogeneic islet transplantation by (-) 15-deoxyspergualin in the rat.

Authors:  P K Walter; G Dickneite; H U Schorlemmer; H H Sedlacek; S Jäger; G Feifel; G Seitz
Journal:  Diabetologia       Date:  1987-01       Impact factor: 10.122

7.  Glucose and insulin changes following a renoportal shunt in streptozotocin diabetic rats with pancreatic islet isografts under the kidney capsule.

Authors:  H Reece-Smith; P McShane; P J Morris
Journal:  Diabetologia       Date:  1982-10       Impact factor: 10.122

Review 8.  Cyclosporine: immunology, toxicity and pharmacology in experimental animals.

Authors:  A W Thomson; P H Whiting; J G Simpson
Journal:  Agents Actions       Date:  1984-10

Review 9.  The Spleen as an Optimal Site for Islet Transplantation and a Source of Mesenchymal Stem Cells.

Authors:  Naoaki Sakata; Gumpei Yoshimatsu; Shohta Kodama
Journal:  Int J Mol Sci       Date:  2018-05-07       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.